Published in Ann Thorac Surg on November 01, 2006
Lung transplantation for cystic fibrosis. Proc Am Thorac Soc (2009) 0.83
Preservation solutions for cardiac and pulmonary donor grafts: a review of the current literature. J Thorac Dis (2014) 0.82
Geographic distance between donor and recipient does not influence outcomes after lung transplantation. Ann Thorac Surg (2011) 0.81
Low potassium dextran is superior to University of Wisconsin solution in high-risk lung transplant recipients. J Heart Lung Transplant (2010) 0.79
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant (2002) 5.49
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
Single-centre experience of donation after cardiac death. Med J Aust (2012) 2.60
Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant (2007) 1.88
Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis (2004) 1.68
Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device. J Heart Lung Transplant (2009) 1.58
Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant (2008) 1.54
Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol (2010) 1.48
Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation (2004) 1.45
Total leukocyte control for elective coronary bypass surgery does not improve short-term outcome. Ann Thorac Surg (2005) 1.43
Predictors of independent lung ventilation: an analysis of 170 single-lung transplantations. J Thorac Cardiovasc Surg (2007) 1.42
Feasibility and utility of a lung donor score: correlation with early post-transplant outcomes. Ann Thorac Surg (2007) 1.40
Unilateral radiographic abnormalities after bilateral lung transplantation: exclusion from the definition of primary graft dysfunction? J Thorac Cardiovasc Surg (2006) 1.39
Unexpected donor pulmonary embolism affects early outcomes after lung transplantation: a major mechanism of primary graft failure? J Thorac Cardiovasc Surg (2005) 1.39
In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate (2014) 1.35
A feasibility and safety study of bronchoscopic thermal vapor ablation: a novel emphysema therapy. Ann Thorac Surg (2009) 1.22
A review of lung transplant donor acceptability criteria. J Heart Lung Transplant (2003) 1.16
The potential for bronchoscopic lung volume reduction using bronchial prostheses: a pilot study. Chest (2003) 1.16
Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation (2003) 1.15
Cardiac surgery in patients with a history of malignancy: increased complication rate but similar mortality. Heart Lung Circ (2012) 1.11
Clinical application of airway bypass with paclitaxel-eluting stents: early results. J Thorac Cardiovasc Surg (2007) 1.11
Acute fibrinoid organizing pneumonia after lung transplantation. Am J Respir Crit Care Med (2013) 1.10
Lung transplantation: does age make a difference? Med J Aust (2007) 1.07
Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant (2007) 1.06
Occlusion of a broncho-cutaneous fistula with endobronchial one-way valves. Ann Thorac Surg (2005) 1.03
Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. J Heart Lung Transplant (2005) 1.02
Strategies to optimize the use of currently available lung donors. J Heart Lung Transplant (2004) 0.99
MicroRNA-17-92, a direct Ap-2α transcriptional target, modulates T-box factor activity in orofacial clefting. PLoS Genet (2013) 0.98
Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. Respirology (2008) 0.98
Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant (2007) 0.97
Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant (2008) 0.95
Massage therapy for cardiac surgery patients--a randomized trial. J Thorac Cardiovasc Surg (2012) 0.95
Interleukin-17 and airway inflammation: a longitudinal airway biopsy study after lung transplantation. J Heart Lung Transplant (2007) 0.95
Extracorporeal membrane oxygenation after lung transplantation: evolving technique improves outcomes. Ann Thorac Surg (2004) 0.93
Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography. Eur J Heart Fail (2012) 0.90
In vivo irreversible electroporation kidney ablation: experimentally correlated numerical models. IEEE Trans Biomed Eng (2014) 0.90
Long-term outcomes from bronchoscopic lung volume reduction using a bronchial prosthesis. Respirology (2011) 0.89
A donor history of smoking affects early but not late outcome in lung transplantation. Transplantation (2004) 0.89
The effects of metallic implants on electroporation therapies: feasibility of irreversible electroporation for brachytherapy salvage. Cardiovasc Intervent Radiol (2013) 0.88
Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation (2005) 0.88
Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg (2006) 0.87
Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a pathophysiologic review. J Heart Lung Transplant (2012) 0.86
Availability of lungs for transplantation: exploring the real potential of the donor pool. J Heart Lung Transplant (2008) 0.86
Airway vascular changes after lung transplant: potential contribution to the pathophysiology of bronchiolitis obliterans syndrome. J Heart Lung Transplant (2005) 0.85
Phrenic nerve injury during cardiac surgery: mechanisms, management and prevention. Heart Lung Circ (2013) 0.85
Update on lung transplantation: programmes, patients and prospects. Eur Respir Rev (2012) 0.84
A reinforced sternal wiring technique for transverse thoracosternotomy closure in bilateral lung transplantation: from biomechanical test to clinical application. J Thorac Cardiovasc Surg (2007) 0.84
Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ (2003) 0.83
Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant (2006) 0.83
Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. Diabetes (2010) 0.83
Techniques of reconstruction for inadequate donor left atrial cuff in lung transplantation. Ann Thorac Surg (2006) 0.82
A practical approach to clinical lung transplantation from a Maastricht Category III donor with cardiac death. J Heart Lung Transplant (2007) 0.82
High donor age, low donor oxygenation, and high recipient inotrope requirements predict early graft dysfunction in lung transplant recipients. J Heart Lung Transplant (2005) 0.82
Impact of commonly used transplant immunosuppressive drugs on human NK cell function is dependent upon stimulation condition. PLoS One (2013) 0.82
Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial. Heart Lung Circ (2010) 0.81
Cranial leiomyosarcoma in an Epstein-Barr virus (EBV)-mismatched lung transplant recipient. J Heart Lung Transplant (2007) 0.81
Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics (2006) 0.81
Early changes in basement membrane thickness in airway walls post-lung transplantation. J Heart Lung Transplant (2005) 0.80
Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology (2008) 0.80
Preliminary report of the safety and efficacy of hyperbaric oxygen therapy for specific complications of lung transplantation. J Heart Lung Transplant (2006) 0.80
Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am J Respir Crit Care Med (2005) 0.80
Impaired muscle Ca2+ and K+ regulation contribute to poor exercise performance post-lung transplantation. J Appl Physiol (1985) (2003) 0.79
Bronchiolitis obliterans syndrome leads to a functional deterioration of the acinus post lung transplant. Thorax (2013) 0.79
Evaluation of the oxygenation ratio in the definition of early graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg (2005) 0.79
Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. Antimicrob Agents Chemother (2013) 0.79
Feasibility and Safety of a Transthoracic Pneumostoma Airway Bypass in Severe Emphysema Patients. Respiration (2017) 0.79
The principles of metabolic therapy for heart disease. Heart Lung Circ (2003) 0.78
Bronchial hyperresponsiveness and the bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant (2005) 0.78